ACG Wealth increased its position in Celgene Co. (NASDAQ:CELG) by 24.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 32,021 shares of the biopharmaceutical company’s stock after purchasing an additional 6,228 shares during the quarter. ACG Wealth’s holdings in Celgene were worth $3,342,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Arcadia Investment Management Corp MI grew its stake in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares during the last quarter. Robecosam AG acquired a new position in Celgene in the 3rd quarter valued at about $114,000. Capital Bank & Trust Co grew its position in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 517 shares in the last quarter. Guidant Wealth Advisors acquired a new position in shares of Celgene during the 3rd quarter worth approximately $119,000. Finally, Balentine LLC grew its position in shares of Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares in the last quarter. 78.60% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

A number of research analysts have issued reports on CELG shares. Mizuho restated a “buy” rating and set a $128.00 target price on shares of Celgene in a research report on Sunday, February 4th. Credit Suisse Group set a $125.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Monday, January 8th. Cann restated a “buy” rating and set a $163.00 target price on shares of Celgene in a research report on Thursday, February 15th. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 target price on the stock. in a research report on Monday, December 18th. Finally, Oppenheimer set a $166.00 target price on shares of Celgene and gave the stock a “buy” rating in a research report on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $127.78.

In related news, insider Mark J. Alles acquired 3,260 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was acquired at an average price of $91.90 per share, with a total value of $299,594.00. Following the purchase, the insider now directly owns 178,904 shares in the company, valued at $16,441,277.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the transaction, the director now directly owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. In the last three months, insiders sold 41,120 shares of company stock valued at $3,879,509. 0.95% of the stock is owned by insiders.

Celgene Co. (NASDAQ:CELG) opened at $86.91 on Friday. The company has a market cap of $66,394.54, a P/E ratio of 24.28, a P/E/G ratio of 0.62 and a beta of 1.58. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80. Celgene Co. has a 52 week low of $86.55 and a 52 week high of $147.17.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.61 EPS. equities analysts expect that Celgene Co. will post 7.66 earnings per share for the current year.

Celgene declared that its board has initiated a stock buyback plan on Wednesday, February 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: “Celgene Co. (CELG) Shares Bought by ACG Wealth” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/celgene-co-celg-shares-bought-by-acg-wealth/1958841.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.